International Approvals: Preotact, Tysabri, Relenza

The EU has approved a recombinant parathyroid hormone product for subcutaneous injection (Preotact) and natalizumab intravenous infusion (Tysabri); Australia has approved a new indication for zanamivir oral inhalation (Relenza with Diskhaler).Yael Waknine

Continue to International Approvals: Preotact, Tysabri, Relenza on Medscape Medical News Headlines.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz